menu
    • menu

    Company profile for CytoImmune Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CytoImmune Therapeutics, LLC develops novel, coordinated immunotherapy solutions for patients. Our CoalesceNT™ platform harnesses the power of bispecific antibody (biAb) and chimeric antigen receptor (CAR) technology to coordinate an immune response with both natural killer (NK) and T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic immune response that reflects natural ...
    CytoImmune Therapeutics, LLC develops novel, coordinated immunotherapy solutions for patients. Our CoalesceNTâ„¢ platform harnesses the power of bispecific antibody (biAb) and chimeric antigen receptor (CAR) technology to coordinate an immune response with both natural killer (NK) and T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic immune response that reflects natural immunity.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CytoImmune TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1218 S 5th Ave, Monrovia, CA 91016 469.222.2350
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://cytoimmune.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Matica Bio And CytoImmune Partner On Cell Therapy Program
    Matica Bio And CytoImmune Partner On Cell Therapy Program

    10 Oct 2024

    // CONTRACTPHARMA

    https://www.contractpharma.com//contents/view_breaking-news/2024-10-10/matica-bio-cytoimmune-partner-to-advance-clinical-cell-therapy-program/?widget=listSection

    CONTRACTPHARMA
    10 Oct 2024
    Share Share
    CytoImmune to Present Preclinical Data Highlighting Potential of TRACK-NK Cells
    CytoImmune to Present Preclinical Data Highlighting Potential of TRACK-NK Cells

    10 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221110005445/en

    BUSINESSWIRE
    10 Nov 2022
    Share Share
    CytoImmune Therapeutics Appoints Remus Vezan as Chief Medical Officer
    CytoImmune Therapeutics Appoints Remus Vezan as Chief Medical Officer

    07 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220907005234/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share
    CytoImmune and City of Hope Begin Dosing in PI Trial Evaluating NKCT
    CytoImmune and City of Hope Begin Dosing in PI Trial Evaluating NKCT

    28 Jul 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220728005134/en

    BUSINESSWIRE
    28 Jul 2022
    Share Share
    CytoImmune Presents Data on NK Cell-Based Therapies for Hematology & Solid Tumor
    CytoImmune Presents Data on NK Cell-Based Therapies for Hematology & Solid Tumor

    11 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220411005293/en

    BUSINESSWIRE
    11 Apr 2022
    Share Share
    CytoImmune to Participate in Upcoming April Investor Conferences
    CytoImmune to Participate in Upcoming April Investor Conferences

    07 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220407005960/en

    BUSINESSWIRE
    07 Apr 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search